PTC Therapeutics

PTC Therapeutics, Inc. (PTC) is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. While our discovery programs are directed at targets in multiple therapeutic areas, we are focusing particularly on the development of treatments for rare and very rare disorders including Duchenne Muscular Dystrophy (DMD).

PTC Therapeutics is pleased to support the 2018 MIMS Learning Live Red Flags event.